Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline Review, H1 2017

  • ID: 4327557
  • Report
  • 137 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • EpiZyme Inc
  • Merck & Co Inc
  • Novartis AG
  • Pfizer Inc
  • Plexxikon Inc
  • MORE
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline Review, H1 2017

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline Review, H1 2017, provides an overview of the Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) (Oncology) pipeline landscape.

Malignant peripheral nerve sheath tumors (MPNSTs) are sarcomas which originate from peripheral nerves or from cells associated with the nerve sheath, such as Schwann cells, perineural cells, or fibroblasts. Symptoms include lump or swelling in the in the soft tissue, numbness, burning or having that pins and needles feeling, weakness in the affected muscles and dizziness or loss of balance. Treatment includes surgery, radiotherapy and chemotherapy.

Report Highlights:

The latest Pharmaceutical and Healthcare latest pipeline guide Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II and Phase I stages are 7 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) (Oncology)
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • EpiZyme Inc
  • Merck & Co Inc
  • Novartis AG
  • Pfizer Inc
  • Plexxikon Inc
  • MORE
Introduction

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Overview

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Companies Involved in Therapeutics Development

Bexion Pharmaceuticals LLC

EpiZyme Inc

Merck & Co Inc

Millennium Pharmaceuticals Inc

Novartis AG

Pfizer Inc

Plexxikon Inc

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Drug Profiles

axitinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BXQ-350 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

everolimus - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ganetespib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Oncolytic Virus to Target CD46 and SLC5A5 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pembrolizumab - Drug Profile

R&D Progress

pexidartinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sapanisertib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit BRD4 for Malignant Peripheral Nerve Sheath Tumors - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tazemetostat - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Product Development Milestones

Featured News & Press Releases

Dec 26, 2013: UTSW study identifies potential therapeutic target for incurable, rare type of soft-tissue cancer

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma), H1

Number of Products under Development by Companies, H1

Number of Products under Development by Universities/Institutes, H1

Products under Development by Companies, H1

Products under Development by Universities/Institutes, H1

Number of Products by Stage and Target, H1

Number of Products by Stage and Mechanism of Action, H1

Number of Products by Stage and Route of Administration, H1

Number of Products by Stage and Molecule Type, H1

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Bexion Pharmaceuticals LLC, H1

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by EpiZyme Inc, H1

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Merck & Co Inc, H1

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Millennium Pharmaceuticals Inc, H1

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Novartis AG, H1

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Pfizer Inc, H1

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Plexxikon Inc, H1

List of Figures

Number of Products under Development for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma), H1

Number of Products under Development by Companies, H1

Number of Products by Top 10 Targets, H1

Number of Products by Stage and Top 10 Targets, H1

Number of Products by Top 10 Mechanism of Actions, H1

Number of Products by Stage and Top 10 Mechanism of Actions, H1

Number of Products by Routes of Administration, H1

Number of Products by Stage and Routes of Administration, H1

Number of Products by Molecule Types, H1

Number of Products by Stage and Molecule Types, H
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Bexion Pharmaceuticals LLC
  • EpiZyme Inc
  • Merck & Co Inc
  • Millennium Pharmaceuticals Inc
  • Novartis AG
  • Pfizer Inc
  • Plexxikon Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll